An improved trastuzumab-dependent cell-mediated cytotoxicity was reported in a mouse xenograft breast tumour model that was not expressing CD32B, whereas mice deficient in activating FcγRs were unable to supress tumour growth [57]. This evidence concerns the gene FCGR2B and neoplasm.